SCM
SYRE icon

Superstring Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Superstring Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-37,287
Closed -$1.1M – 46
2024
Q3 		$1.1M Sell
37,287
-8,284
-18% -$231K 0.96% 18
2024
Q2 		$1.07M Buy
+45,571
New +$1.54M 1.35% 21

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Superstring Capital Management's SYRE Position: Q4 2024 in Review

Superstring Capital Management sold out of Spyre Therapeutics (SYRE) in Q4 2024, closing a stake of 37,287 shares — an estimated $1.1M sold.

Superstring Capital Management first reported a position in SYRE in Q2 2024 and held it in 2 quarters. The position peaked at $1.1M in Q3 2024. 131 funds tracked by Wall St. Rank hold SYRE as of Q4 2024.

  • Superstring Capital Management reported no remaining Spyre Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Superstring Capital Management sold 37,287 Spyre Therapeutics shares in Q4 2024, an estimated $1.1M.
  • Superstring Capital Management first reported a position in Spyre Therapeutics in Q2 2024 and held it in 2 quarters.
  • Superstring Capital Management's Spyre Therapeutics position peaked at $1.1M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2024.

Based on Superstring Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.